	US 12,226,544 B2
	Brain damage recovery material
Yoshihisa Suzuki, Osaka (JP); Masao Tanihara, Nara (JP); and Mitsuko Isaji, Tokyo (JP)
Assigned to Tazuke Kofukai, Osaka (JP); and Mochida Pharmaceutical Co., Ltd., Tokyo (JP)
Appl. No. 16/645,768
Filed by Tazuke Kofukai, Osaka (JP); and Mochida Pharmaceutical Co., Ltd., Tokyo (JP)
PCT Filed Sep. 13, 2017, PCT No. PCT/JP2017/033094 § 371(c)(1), (2) Date Mar. 9, 2020, PCT Pub. No. WO2019/053822, PCT Pub. Date Mar. 21, 2019.
Prior Publication US 2020/0268931 A1, Aug. 27, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 26/00 (2006.01); B01J 13/00 (2006.01); C08L 5/00 (2006.01); C08L 5/04 (2006.01); C08L 67/04 (2006.01); G01N 3/00 (2006.01)

CPC A61L 26/0023 (2013.01) [A61L 26/009 (2013.01); B01J 13/00 (2013.01); C08L 5/00 (2013.01); C08L 5/04 (2013.01); C08L 67/04 (2013.01); A61L 2430/00 (2013.01); A61L 2430/32 (2013.01); G01N 3/00 (2013.01)]

13 Claims

1. A method of treating brain damage comprising administering to a subject in need thereof a non-tubular brain damage repair material which covers and/or fills a damaged site of a brain, comprising:

(A) a crosslinked product in which a low endotoxin bioabsorbable polysaccharide having a carboxyl group in a molecule thereof is covalently crosslinked with at least one crosslinking reagent selected from a compound represented by general formula (I) below and a salt thereof; and

(B) a bioabsorbable polymer:

R¹HN—(CH₂)_n—NHR² (I)

wherein, R¹and R²each independently represent a hydrogen atom or a group represented by the formula: —COCH(NH₂)—(CH₂)₄—NH₂, and n represents an integer of 2 to 18, wherein the endotoxin content of the bioabsorbable polysaccharide is 500 endotoxin units (EU)/g or less.